American Journal of Clinical Dermatology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Cholestatic Itch: Our Current Understanding of Pathophysiology and Treatments
AbstractHepatic pruritus is common in liver conditions, including cholestasis and nonalcoholic fatty liver disease. The pruritus can be severe enough to diminish sleep and decrease quality of life. The pathophysiology likely involves many molecules and receptors, including bile acids, bilirubin, lysophosphatidic acid (LPA), endogenous opioids, and serotonin. Recent advances suggest a significant role of Mas-related G protein-coupled receptor X4 (MRGPRX4) and autotaxin/LPA as key players in cholestatic pruritus. Further research is needed to develop increasingly targeted therapies with greater efficacy, especially given tha...
Source: American Journal of Clinical Dermatology - July 28, 2022 Category: Dermatology Source Type: research

Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis
ConclusionsContinued tralokinumab treatment plus TCS as needed provides progressive and sustained improvements in AD signs, symptoms, and health-related QoL over 32 weeks.Clinical trial registrationNCT03363854; study start date: 22 February 2018; primary completion date: 8 March 2019; study completion date: 26 September 2019. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - July 20, 2022 Category: Dermatology Source Type: research

Update in Diagnosis and Management of Primary Cutaneous B-Cell Lymphomas
AbstractPrimary cutaneous lymphomas are a rare group of diseases, with an estimated incidence of 0.5 –1 case per 100,000 people per year. Primary cutaneous B-cell lymphomas (pCBCLs) represent 25–30% of all primary cutaneous lymphomas. There are three main subtypes of pCBCL: primary cutaneous marginal zone lymphoma, primary cutaneous follicle center lymphoma, and primary cutaneous diffuse large B-cell lymphoma, leg type. Cutaneous B-cell lymphomas have a broad spectrum of clinical presentations, which makes diagnostic and therapeutic strategies challenging. To date, treatment recommendations for cutaneous B-cell lymphom...
Source: American Journal of Clinical Dermatology - July 19, 2022 Category: Dermatology Source Type: research

Suggestions for a New Clinical Classification Approach to Panniculitis Based on a Mayo Clinic Experience of 207 Cases
ConclusionWe present an updated classification schema of panniculitides based on clinical findings. The primary distinctions are based on ulceration, location, and number of lesions. Although complete distinction of all panniculitides based on clinical examination alone is not possible, we hope the proposed schema allows clinicians to tailor  differential diagnoses. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - July 18, 2022 Category: Dermatology Source Type: research

Oncodermatology: Advancing the Science and Care of Cancer Patients and Survivors
(Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - July 5, 2022 Category: Dermatology Source Type: research

Cutaneous Manifestations of Inflammatory Bowel Disease: A Basic Overview
AbstractInflammatory bowel disease (IBD) is a chronic inflammatory condition of the gastrointestinal (GI) tract that is subdivided into Crohn ’s disease (CD) and ulcerative colitis (UC). CD is characterized by involvement of the entire GI tract, while UC mainly affects the distal GI tract. Moreover, both CD and UC can present with extraintestinal manifestations (EIMs) of the disease affecting multiple organ systems including the hepatob iliary tract, kidney, bones, eyes, joints, and skin. These complications can cause significant morbidity and negatively impact the quality of life for IBD patients. Although the pathogene...
Source: American Journal of Clinical Dermatology - July 1, 2022 Category: Dermatology Source Type: research

Candida Infection Associated with Anti-IL-17 Medication: A Systematic Analysis and Review of the Literature
AbstractAnti-interleukin (IL)-17 agents have shown excellent therapeutic efficacy in patients with psoriasis and are expected to be expanded to other chronic inflammatory diseases. However, patients receiving anti-IL-17 agents are at an increased risk of developingCandida infection, with some agents reported to increase the incidence in a dose-dependent manner. Interleukin-17 is secreted by the Th17 subset of CD4+ lymphocytes, CD8+ T cells, and innate cells, including natural killer T cells, lymphoid tissue inducer cells, innate lymphoid cells, and γδ-T cells, and plays an important role in antifungal defense. Genetic de...
Source: American Journal of Clinical Dermatology - July 1, 2022 Category: Dermatology Source Type: research

Time to Relapse After Discontinuing Systemic Treatment for Psoriasis: A Systematic Review
ConclusionBiological agents are associated with a longer time to relapse than oral systemic agents after drug discontinuation. Among biologicals, IL-23 antagonists are associated with the longest time to relapse. These findings may have clinical consequences for the selection of systemic agents when intermittent treatment is necessary. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - July 1, 2022 Category: Dermatology Source Type: research

Oncodermatology: Advancing the Science and Care of Cancer Patients and Survivors
(Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - July 1, 2022 Category: Dermatology Source Type: research

Treatment of Hyperhidrosis: An Update
AbstractHyperhidrosis is a dermatosis presenting as pathologically excessive focal or generalized sweating. The stigmatizing nature of hyperhidrosis may cause patients to feel embarrassment and apprehension about their symptoms and experience a significant decrease in well-being. Severe cases of hyperhidrosis can also increase the risk of developing psychiatric and somatic comorbidities. Conventional non-surgical treatments of hyperhidrosis include aluminum salts, iontophoresis, botulinum toxin injections, and oral glycopyrronium. In recent years, new topical anticholinergic medications and devices have emerged that may im...
Source: American Journal of Clinical Dermatology - July 1, 2022 Category: Dermatology Source Type: research

Combination Therapy with Apremilast and Biologics for Psoriasis: A Systematic Review
ConclusionEvidence for combined treatment with apremilast and biologics is limited and restricted to retrospective studies of various quality. Based on available data, apremilast may constitute an efficacious and safe add-on treatment to biologic therapy, but properly conducted clinical investigations are needed. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - June 23, 2022 Category: Dermatology Source Type: research